Claire Houppe

Université Paris Est, INSERM U955
Creteil, 94010, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Paclitaxel-loaded nanostructured lipid carriers surface-functionalized with N6L for pancreatic cancer.

Paclitaxel-loaded nanostructured lipid carriers surface-functionalized with N6L for pancreatic cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 15, 2026

Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy" [Eur. J. Pharmacol. 991 (2025) 177310].

Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy" [Eur. J. Pharmacol. 991 (2025) 177310].

Journal: European journal of pharmacology

Published: February 28, 2025

TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion.

TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion.

Journal: Journal for immunotherapy of cancer

Published: October 04, 2024

Synthesis and physico-chemical investigation of thiolated dextran derivative: Design and application of a redox-responsive drug delivery system.

Synthesis and physico-chemical investigation of thiolated dextran derivative: Design and application of a redox-responsive drug delivery system.

Journal: International journal of biological macromolecules

Published: August 29, 2024

Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265.

Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265.

Journal: Cancers

Published: October 21, 2022

Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression.

Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression.

Journal: Cancers

Published: July 01, 2022

Polymerization-Induced Self-Assembly (PISA) for in situ drug encapsulation or drug conjugation in cancer application.

Polymerization-Induced Self-Assembly (PISA) for in situ drug encapsulation or drug conjugation in cancer application.

Journal: Journal of colloid and interface science

Published: November 30, 2021

Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma.

Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma.

Journal: Cancers

Published: March 30, 2021

Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.

Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.

Journal: Nanotechnology

Published: December 22, 2020

Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis.

Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: July 19, 2019

Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy.

Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy.

Journal: Oncotarget

Published: June 21, 2017

Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature.

Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature.

Journal: Cancer research

Published: February 02, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026